Artemis Program

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

system
By system
May 13, 2026 • 60 views
Original source: GlobeNewswire
Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

- Duchenne (SGT-003): First participant dosed in the Phase 3 IMPACT DUCHENNE clinical trial, receipt of positive opinion on the Company’s Pediatric Investigation Plan from the European Medicines Agency and Orphan drug designation from the European Commission …

system
system

Article Author

Related Articles
Detecting Atomic Weapons in Space
1 hour ago
Could Astronauts Grow Rice on the Moon?
1 hour ago
Trump gifts Artemis astronauts a flag from the US Capitol to plant on the moon
5 hours ago
'This is the future of spatial intelligence': Vantor unveils stunning 3D satellite views of Earth (photos)
7 hours ago
Topic Tags
Nasa Artemis Ii Lunar Mission Space Launch System Artemis Iii Orion Spacecraft Blue Origin Spacex Artemis Program Reid Wiseman Deep Space New Glenn Commercial Launch Low Earth Orbit Orion Tiangong Chinese National Space Administration Crewed Spaceflight Pbs Documentary Moon Exploration Ng 3 Rocket Reusability Be 4 Cape Canaveral Vulcan Centaur United Launch Alliance Space Force Solid Rocket Boosters National Security Space Launch Gem 63xlmotor
Stay Updated

Subscribe to our newsletter for the latest news